miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6  by Zhu, Xiaolan et al.
FEBS Letters 587 (2013) 73–81journal homepage: www.FEBSLetters .orgmiR-137 inhibits the proliferation of lung cancer cells
by targeting Cdc42 and Cdk60014-5793/$36.00 Crown Copyright  2012 Published by Elsevier B.V. on behalf of Federation of European Biochemical society. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2012.11.004
⇑ Corresponding author.
E-mail address: zxl0122721@sina.com (W. Xu).Xiaolan Zhu a, Yuefeng Li b, Huiling Shen a, Hao Li a, Lulu Long a, Lulu Hui a, Wenlin Xu a,⇑
a The Fourth Afﬁliated Hospital of Jiangsu University, 20 Zhengdong Road, Zhenjiang, Jiangsu 212000, China
b The Afﬁliated Hospital of Jiangsu University, 438 Jiefang Road, Zhenjiang, Jiangsu 212001, China
a r t i c l e i n f o a b s t r a c tArticle history:
Received 15 September 2012
Revised 20 October 2012
Accepted 2 November 2012
Available online 21 November 2012
Edited by Tamas Dalmay
Keywords:
miR-137
Lung cancer
Cdc42
Cdk6MicroRNAs (miRNA) have emerged as key players in carcinogenesis. Here, we investigated the role of
miR-137 in the pathogenesis of lung cancer. The downregulation of miR-137 in lung cancer cells
could be rescued following inhibition of DNA methylation. Ectopic expression of miR-137 in lung
cancer cells signiﬁcantly downregulated Cdc42, Cdk6 and induced G1 cell cycle arrest, leading to a
signiﬁcant decrease in cell growth in vivo and in vitro. Further, both Cdc42 and Cdk6 were con-
ﬁrmed as targets of miR-137.
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Lung cancer, with high incidence and mortality, has long been
the most deadly cancer disease. Most lung cancers are carcinomas,
and non-small cell lung carcinoma (NSCLC) accounts for more than
80% of these [1]. However, up to date, the molecular mechanisms
underlying the development of NSCLC are still poorly understood.
MicroRNAs (miRNA) are small non-coding RNAs that bind to
partially complementary recognition sequences of mRNA, causing
either degradation or inhibition of translation, thus effectively
silencing their mRNA target [2]. The identiﬁcation of miRNA as
the causative force for chronic lymphocytic leukemia opened a
new avenue in the ﬁeld of oncogenesis. Nowadays, although the
global alteration of miRNA expression becomes a hallmark of
tumorigenesis, the researches addressing the roles of miRNAs in
cellular transformation and tumorigenesis are still at an early
stage. miR-137 was located at the region on chromosome 1p22,
has been found to be downregulated in several cancers including
colorectal cancer [3,4], glioblastoma multiforme [5,6], gastric can-
cer [7], melanoma [8,9], oral cancer [10], breast cancer [11] and
squamous cell carcinoma of the head and neck (SCCHN) [12,13]
by methylation of the miR-137 CpG island. In glioblastoma multi-
forme and oral squamous cell carcinoma, ectopic transfection of
miR-137 could induce cell cycle arrest by down-regulation of
CDK6 [6,14]. In colorectal cancer [3,4], miR-137 was shown to tar-get CDC42, inducing cell cycle G1 arrest and inhibiting invasion.
Recently, miR-137 has been reported to target the CtBP1, a co-
repressor of various tumor suppressor genes [8]. In breast cancer,
miR-137 induced ERRa-knockdown contributed to the impaired pro-
liferative and migratory capacity [11]. In uveal melanoma, miR-137
acted as a tumor suppressor in cell proliferation through down-
regulation of the targets MITF and CDK6 [15]. It is reported that in
lung adenocarcinoma, miR-137 downregulated at more than 20-fold
as compared with corresponding normal lung tissue [16]. However,
the expression levels and downstream target genes of miR-137 as
well as its biological roles in lung cancer cells are still unknown.
Cell division cycle 42 (Cdc42), a Rho GTPase family member,
was involved in cell transformation, proliferation, survival, inva-
sion and metastasis of human cancer cells. Overexpression of
Cdc42 has been reported in several types of human cancer includ-
ing lung cancer [17,18]. Furthermore, the up-regulated Cdc42
activity may impair c-Cbl-mediated EGFR degradation, contribute
to EGFR hyperactivity and induce proteasomal degradation of
p21CIP1 leading to an increase in cell proliferation and migration
[19]. In contrast, downregulation of Cdc42 signals can inhibit
anchorage-independent growth and induce apoptosis via the
PI(3)K-Akt and ERK signaling cascades and the p53 tumor suppres-
sor [20]. Consistent with these reports, Cdc42 silencing by small
hairpin RNA was able to reverse the metastatic and growth behav-
ior of human colorectal cancer cells, bladder cancer cells and lung
cancer [4,17,18,21]. Frequent alteration in the expression of Cdc42
was detected in NSCLC, but the mechanism(s) underlying the alter-
ation in expression have not been completely determined.
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family, was known to play important roles in the cell cycle though
binding to cyclin D began the phosphorylation of retinoblastoma
(p-Rb) complexed to transcription factors E2F/DP. Following Rb
phosphorylation, cyclin E activates Cdk2 to effect further
phosphorylation of Rb, thereby enabling the cells to cross the G1
restriction point [22]. Moreover, several studies have shown
that ampliﬁcation, overexpression or activation of Cdk6 was
associated with human glioblastoma [23], medulloblastoma [24]
and lung adenocarcinomas [25], and it was hypothesized that
overexpression of Cdk6 may result in accelerated progression
through the G 1/S-phase checkpoint of the cell cycle, thus leading
to increased proliferation and reduction in DNA repair capacity [26].
Given that Cdc42 and Cdk6 were the key transducers of prolif-
erative signals in G1cell cycle regulation, which were found to be
signiﬁcantly up-regulated in NSCLC, have been comforted to be tar-Fig. 1. The restoration of miR-137 inhibits the proliferation and induces cell cycle G1 arr
and lung cancer cell lines. The results are presented as fold change of expression levels in
expression level of miR-137 in A549 and H460 cells transfected with miR-137. (C,D) Ecto
cell cycle G1 arrest in A549 and H460 cells. (G,H) The apoptosis of A549 and H460 cellsgets of miR-137 in cancers previously [6,8,14,15], so they were of
particular interest to us. In our study, we identiﬁed Cdc42 and
Cdk6 were targets of miR-137, the down-regulated miRNA in lung
cancer cells. Moreover, the restoring expression of miR-137 could
efﬁciently suppress lung cancer cells proliferation in vivo and
in vitro partially through regulating the expression of Cdc42 and
Cdk6.
2. Materials and methods
2.1. Cell lines and cell culture
The NSCLC cell lines A549, NCI-H460, and NCI-H520 and the
normal fetal lung ﬁbroblast cell line (MRC5) were obtained from
Shanghai Institute of Cell Biology, China Academy of Sciences.
NSCLC cells were cultured in RPMI1640 and MRC5 in MEM con-est in NSCLC cells. (A) Real-time RT-PCR analysis for miR-137 expression level MRC5
the NSCLC cell lines relative to the the normal fetal lung ﬁbroblast cell line. (B) The
pic miR-137 inhibits the proliferation of A549 and H460 cells. (E,F) miR-137 induces
(⁄P < 0.05).
X. Zhu et al. / FEBS Letters 587 (2013) 73–81 75taining 10% fetal calf serum (Gibco BRL, Grand Island, NY) in a
humidiﬁed atmosphere containing 5% CO2 at 37 C.
2.2. Real-time quantiﬁcation of miRNAs and mRNA by stem-loop RT-
PCR
Total RNA was extracted from the NSCLC cells and the normal
cells using Trizol (Invitrogen). Expression of mature miRNAs and
mRNA was assayed using stem-loop RT followed by real-time
PCR analysis as previously described [27]. (The primers: miR-137,
FW,5’-TATTGCTTAAGAATACGCGTAG,RV,50-AACTCCAGCAGGACCAT
GTGAT-30. Cdc42, FW, 50-GATGGTGCTGTTGGTAAA-30, RV, 50-TAA
CTCAGCGGTCGTAAT-30. Cdk6, FW, 50-CGTGGTCAGGTTGTTT GAT
GTG-30, RV, 50-ACTCGGTGTGAATGAAGAAAGTCC-30.) The relative
amount of each miRNA was normalized to U6 snRNA. Expression
levels of Cdc42 and Cdk6 mRNA were normalized to b-actin mRNA.
The relative expression levels of each sample were measured using
the 244CT method [28].
2.3. microRNA transfection assay
The miR-137 mimic, and negative miRNA mimic control
(mimic-NC: 50-UUCUCCGAACGUGUCACGUTT-30) were chemicallyFig. 2. Cdc42 and Cdk6 are targets of miR-137. (A,B) Speciﬁc locations of the binding site
and Cdk6 30UTR relative luciferase activity in mimic-transfected A549 cells. (C,D) The m
analysis of A549 cells after transfection for Cdc42 or Cdk6 protein expression. b-Actin wsynthesized by Shanghai GenePharma Company (Shanghai, China).
NSCLC cells were plated in 6-well plates (4  105 cells/well) and
transfected with 100 nM of the miR-137 mimic, or negative miRNA
mimic control using Lipofectamine 2000 (Invitrogen, Long Island,
NY) according to the manufacturer’s protocol as previously de-
scribed [27].
2.4. Cell proliferation assay
NSCLC cells were seeded in 96-well plates (3  103 cells/well),
after transfection for 24 h, cell proliferation was assessed by MTS
assay, using an assay kit (CellTiter 96 AQueous; Promega, Madison,
WI) according to the manufacturer’s protocol. Brieﬂy, solution re-
agent was added to each well and incubated at 37 C for 3 h. Then
cell proliferation was assessed by measuring the absorbance at
490 nm by a microtiter plate reader (Molecular Devices, Sunnyvale,
CA).
2.5. Cell cycle assay
Seventy two hour after transfection. NSCLC cells were trypsini-
zed. Cell pellets harvested by centrifugation were washed for twice
with ice-cold PBS and ﬁxed with ice-cold 70% ethanol for 48 h ats were marked. The luciferase reporter assay showed a signiﬁcant decrease in Cdc42
RNA level of Cdc42 and Cdk6 in A549 cells after transfection. (E,F) Western blot
as detected as the loading control (⁄P < 0.05).
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PI/RNase staining followed by ﬂuorescence-activated cell sorter
scan (FACS) analysis (Becton Dickinson, Mountain View, CA,
USA). The percentage of cells in each phase of the cell cycle was
estimated using ELITE software.
2.6. Evaluation of apoptosis
The apoptosis of NSCLC cells was detected using Annexin V/FITC
and PI apoptosis detection kit (Becton Dickinson, Franklin Lakes,
USA). Brieﬂy, 24 h after transfection, NSCLC cells were harvested
and suspended in the Annexin-binding buffer (1  106 cells/ml).
Thereafter, cells were incubated with Annexin V–FITC and PI for
15 min at room temperature in the dark, ﬂow cytometry was used
to detect apoptosis of the NSCLC cells as previously described [29].
2.7. Luciferase reporter assays
The putative target sites of the human Cdc42 or Cdk6 30UTR seg-
ments for miR-137 were ampliﬁed using Pyrobest DNA polymerase
(Fermentas) and then cloned into the XbaI site of pGL3 control
(Promega, Madison, USA). The mutated putative miR-137 binding
site in the Cdc42 or Cdk6 30UTR was generated using the Quick
change site-directed mutagenesis kit (Stratagene, Cedar Creek,
USA) according to the manufacturer’s protocol. (The primers :
Cdc42 30UTR: FW, 50-GCTCTAGAGCCCTTTCTGCACAGC-30, RV, 50-C
TCTAGAGCTAACCACTG GTTAATG-30. Mut-Cdc42 30UTR: FW, 50-G
CTACTAGTTTAAATCAAACTAAAGAT-30, RV, 50-TTAGTATGATGCCG-
ACA CCAG-30. CDK6 30UTR: FW, 50-AGCTTGATCACA-GAAATATT
GCTAGCTGATACATATTATTGCATTTCATAAAACTA-30, RV, 50-CTAGTA
GTTTTATGAAATGCAATAATATGTATCAGCTAGCAATATTTCTGTGATCA-
30, Mut-CDK6 30UTR: FW, 50-AGCTT-GATCACAGAAATTAA CGAAGCT
GATACATATTATTGCATTTCATAAAACTA-30, RV, 50-CTAGTAGTTTTAT-
GAAATGCAATAATATGTATCAGCTTCGTTAATTTCTGTGATCA-30). A549
cells were plated into 24-well plates (3  104 cells/well). One day
later, cells were co-transfected with 800 ng luciferase vector,
including the 30UTR of Cdc42 or Cdk6, and miR-137 mimic or mimicFig. 3. Downregulation of Cdc42 and Cdk6 inhibits the proliferation of A549 cells and ind
The cell cycle of A549 cells was analyzed after transfection (⁄P < 0.05).control at a ﬁnal concentration of 100 nM with Lipofectamine
2000. Luciferase assays and activity were performed by using the
dual Luciferase reporter assay system (Promega) 48 h after
transfection.
2.8. Transfection
Cdc42 siRNA(Si-Cdc42) and Cdk6 siRNA (Si-Cdk6) were ob-
tained from Qiagen Inc. (Valencia, CA), the recombinant plasmid
eukaryotic expression vector pcDNA3.1–Cdc42 (Cdc42),
pcDNA3.1–Cdk6 (Cdk6) and the empty vector control (pcDNA3.1)
were purchased from Cell Signaling Technology, Inc (Beverly,
USA), A549 cells were plated at a density of 3  104 cells/well in
a 6 well plate, Si-Cdc42, Si-Cdk6, negative control siRNA (50-UU-
CUCCGAACGU-GUCACGUTT-30), pcDNA3.1–Cdc42, pcDNA3.1–
Cdk6 or pcDNA3.1 was transfected into cells with Lipofectamine
2000 according to the manufacturer’s protocol. The cells were pre-
pared for next experiments 48 h after transfection.
2.9. Western blot assay
Fourty eight hour after transfection, proteins from each group
were separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) and then transferred to polyvinyli-
dene diﬂuoride membranes (PVDF; Bio-Rad). The membranes were
blocked and then probed with antibodies against Cdc42, Cdk6, cy-
clin D1, p-Rb (Santa Cruz Biotechnology, Santa Cruz, USA), Akt,
phosphor-Akt (p-Akt), ERK1/2, phosphor-ERK1/2 (p-REK1/2) (Cell
Signaling Technology, MA, USA), and b-actin (Sigma). After wash-
ing, the blots were incubated with horseradish peroxidase-conju-
gated secondary antibodies.
2.10. Demethylation and deacetylation assays
A549 cells were seeded at 1  105 cells/well of a six-well plate
incubated for 24 h. Then 1 or 5 lM 5-aza-20-deoxycytidine (5-
aza-dC) (Sigma, St. Louis, MO), a DNA hypomethylating agent,uces G1 arrest. (A,B) Cell proliferation assay was carried out after transfection. (C,D)
Fig. 4. miR-137 inﬂuences cell proliferation in A549 cells partly through suppression of Cdc42 and Cdk6. (A,B) Real-time RT-PCR analysis for Cdc42 and Cdk6 mRNA level.
(C,D) Western blot analysis for Cdc42 and Cdk6 protein level in A549 cells after transfection normalized to b-actin. (E,F) Re-expression of Cdc42 or Cdk6 in A549 cells
transfected with miR-137 partially rescued the impaired proliferation capacity. (G,H) Re-expression of Cdc42 or Cdk6 in A549 cells transfected with miR-137 partially rescued
the arrested cell cycle progression.
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100 ng/ml, Sigma), a histone deacetylase inhibitor, was added for
12 h. For the combination study, 1 or 5 lM 5-aza-dC was present
for the ﬁrst 72 h, and TSA was added for the last 12 h. The media
containing drugs were changed every 24 h.2.11. Lung cancer xenograft
Transient miRNA expression system was simple and effective
[30–32]. Because the expression of miRNAs weakened over
time, in order to make the suppressive tumor growth more
78 X. Zhu et al. / FEBS Letters 587 (2013) 73–81effective, it was necessary to make sure a sufﬁcient number of
cells were transfected in replicate before injection. As previously
described [27], brieﬂy, A549 cells (5  107) were transfected
with 200 nM miR-137 mimic or mimic control before respective
subcutaneous injection into the left and right ﬂanks of 12 nude
BALB/c mice (SLAC Laboratory, Shanghai, China). Tumor volumes
were calculated using the formula: Tumor volume = length
width2 /2. Tumor growth was monitored weekly and the tu-
mors were harvested 5 weeks after the cells were injected.
2.12. Statistical analysis
The results were representative of three independent experi-
ments and calculated using SPSS version 12.0 software (SPSS, Chi-
cago, IL, USA), presented as mean ± standard deviation and
compared using ANOVA. Statistical signiﬁcance was deﬁned as
P < 0.05.3. Results
3.1. miR-137 expression is downregulated in NSCLC cell lines
We measured miR-137 expression in normal fetal lung ﬁbro-
blast cell line MRC5 and different NSCLC cell lines. The data
showed that compared with MRC5, all NSCLC cell lines lost the
endogenous miR-137 (Fig. 1A), suggesting a role of miR-137 in
NSCLC cells.Fig. 5. Introduction of miR-137 downregulates the expression of cyclin D1, p-ERK1/2 an
expression levels of ERK1/2, Akt, the known downstream signals of Cdc42, were examine
analyzed after transfection, respectively. b-Actin was detected as the loading control.3.2. Ectopic expression of miR-137 inhibits cell proliferation and
induces cell cycle arrest in NSCLC cells
To investigate the impact of miR-137 in cell growth, we in-
creased miR-137 levels in the lung cancer cells (Fig. 1B), relative
to control oligonucleotides, transfection of miR-137 resulted in a
marked decrease of cell number (P < 0.05) (Fig. 1C and D). Then,
we analyzed cell cycle, compared to the negative control, a marked
reduction in the number of cells in the S-phase of the cell cycle and
a marked increase in the number of cells in G0/G1 in both A549 and
H460 cells transfected with miR-137 were detected (P < 0.05), how-
ever, no reproducible differences were observed for cells in G2/M of
the cell cycle (Fig. 1E). To further characterize miR-137-mediated
inhibition of cell proliferation, we analyzed the cells undergoing
apoptosis, no obvious difference was detected in the cells examined
(Fig. 1F). Thus, our date indicates that overexpression of miR-137
results in G1 phase arrest that eventually lead to cell death.
3.3. Cdc42 and Cdk6 are targets of miR-137
To ascertain the molecular mechanisms by which miR-137 in-
duce G0/G1 cell cycle arrest, we assessed expression of Cdc42
and Cdk6, regulators of the cell cycle and differentiation [33,34].
Using the algorithms for target gene prediction, including PicTar,
TargetScan, and miRanda, Cdc42 and Cdk6 were identiﬁed as the
potential targets of miR-137. To test whether miR-137 directly tar-
geted Cdc42 and Cdk6 in NSCLC cells, we constructed luciferase-
reporter genes with Cdc42 and Cdk6 30UTR with or without muta-d p-Rb in A549 and H460 cells. (A,B) Cyclin D1 and the phosphorylation and/or the
d after transfection. (C,D) p-Rb, a downstream target of Cdk6 in A549 and H460 was
Fig. 6. The up-regulation of miR-137 in A549 cells following treatment with DNA
demethylating agents. A549 was treated with 5-aza-dC at 1 lM [Aza(1)] or 5 lM
[(Aza(5)] alone, TSA (100 ng/ml) alone, or combinations of both agents. miR-137
expression was measured.
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with miR-137 addition. Consistent with binding data, a decrease
in relative luciferase activity was noted when the Cdc42 or Cdk6
3UTR was co-transfected with the miR-137 (P < 0.05), however,
no decrease in relative luciferase activity was observed in NSCLC
cells transfected with mutant Cdc42 and Cdk6 30UTR (Fig. 2 A
and B). Furthermore, up-regulation of endogenous miR-137 led
to a signiﬁcant decrease in Cdc42 and Cdk6 expression at both
mRNA level (Fig. 2 C and D) and protein level (Fig. 2 E and F), sug-
gesting that the 30UTR of Cdc42 and Cdk6 are functional target sites
for miR-137 in the NSCLC cells.
3.4. Downregulation of Cdc42 and Cdk6 inhibits cell proliferation and
induces cell cycle G1 arrest in A549 cells
MTS assays showed that cell populations transfected with Si-
Cdc42 or Si-Cdk6 had signiﬁcantly fewer metabolically active cells
than cells transfected with negative control (Fig. 3A and B). Com-
plementary to the ﬁnding that miR-137 inhibited cell proliferation,
ﬂow cytometric analysis showed that A549 cells transfected with
Si-Cdc42 or Si-Cdk6 had G1 arrest compared with negative control
(Fig. 3C and D).
3.5. miR-137 inﬂuences cell proliferation partially through regulating
the expression of Cdc42 and Cdk6
In order to demonstrate that miR-137 acted on the regulation of
cell proliferation through Cdc42 and Cdk6, we tested whether
exogenously expressed Cdc42 and Cdk6 could restore the impaired
proliferative phenotype in A549 cells. Compared to the cells trea-
ted with NC oligos, ectopic expression of Cdc42 and Cdk6 robustly
reversed the decreased expression of Cdc42 and Cdk6 induced by
miR-137 at both transcriptional and protein levels (Fig. 4A–D),
and partially restored the arrested proliferation, however, overex-
pression of Cdc42 and Cdk6 failed to signiﬁcantly promote the cell
proliferation (Fig. 4E–H), probably due to a sufﬁciently high endog-
enous level of Cdc42 and Cdk6 already existing in A549 cells. To-
gether, all of these data indicate that miR-137 induces cell cycle
G1 phase arrest and cell proliferation suppression, at least in part,
via the regulation of Cdc42 and Cdk6.
3.6. Ectopic expression of miR-137 downregulates the immediate
downstream effectors of Cdc42 and Cdk6
The downstream signals of Cdc42 and Cdk6 were examined
after transfection. As shown in (Fig. 5A and B), cyclin D1, p-ERK1/
2, the known downstream signals of Cdc42, were signiﬁcantly re-duced whereas phosphorylated-Akt, total Akt, and total ERK1/2
were not affected when comparing miR-137 transfection to nega-
tive control transfection. Overexpression of miR-137 also reduced
the expression of p-Rb (Fig. 5C and D), a known downstream target
of Cdk6. These signaling effects again mimicked those of Cdc42 or
Cdk6 siRNA knockdown in both A549 and H460 cells. These date
further suggest that the function of miR-137 in the cancer cells is
likely, at least partially through the inhibition of Cdc42 and Cdk6.
3.7. The expression of miR-137 in NSCLC cells can be affected by an
epigenetic mechanism
miR-137 was closely associated with a large CpG island, and it
has been reported to be epigenetically silenced in tumors, further
study validated that it could be activated in Uveal Melanoma
[15] and glioblastomamultiforme cell lines [6] following treatment
with 5-aza-Dc, a DNA methylation inhibitor and/or TSA, a histone
deacetylase inhibitor. We explored, miR-137 expression increased
up to about eightfold in NSCLC cell lines treated with 5-aza-dC, or
and up to about ninefold in cells treated with both 5-aza-dC and
TSA. However, expression of miR-137 remained relatively un-
changed in cells treated with TSA alone (Fig. 6), suggesting that
epigenetic modiﬁcation of regulatory sequences in CpG islands
may contribute to miR-137 silencing in NSCLC cells.
3.8. miR-137 reduces tumor growth in xenograft models of lung cancer
The in vitro data supported a tumor-suppressor role for miR-
137 in NSCLC. To explore whether it had a role in a mouse model
of lung cancer, we assessed the effects of miR-137 on the tumor
growth of xenografts derived from A549 cells. 10 of 12 mice devel-
oped tumors, and miR-137 was clearly seen to inhibit the tumor
growth of A549 xenografts compared to the negative control
(P < 0.05), the weight of the tumors was signiﬁcantly reduced com-
pared to the control tumors on day 35 following surgery resection
(Fig. 7A). After harvesting, Cdc42 and Cdk6 expression levels were
checked. We found that Cdc42 and Cdk6 expression levels were re-
duced compared with the control group (Fig. 7B), suggesting miR-
137 negativly regulates Cdc42 and Cdk6 in vivo.4. Discussion
Evidence suggests that changes in miRNA expression occur fre-
quently in cancers and these variations either contribute to carci-
nogenesis or reﬂect the development and progression of cancers.
Given the previous research, in squamous cell carcinoma of the
head and neck, miR-137 was silenced by hypermethylation [12].
In rectal cancer, miR-137 was up-regulated after preoperative
capecitabine chemoradiotherapy [35], along with miR-124,
miR-137 could induce differentiation of glioblastoma multi-
forme-derived stem cells and glioblastoma multiforme cell cycle
arrest [6]. Here, we were able to show that NSCLC cells displayed
suppressed levels of miR-137 with restoration of activity after
treatment with DNA-hypomethylating agents by the real-time
RT-PCR-based detection methodology, consistent with Dacic’s
study [16]. However, in Huang’s study [36], miR-137 was found
to be upregulated in lung cancer tissues compared to normal lung
tissues using microarray technology, that may due to the expres-
sion of miR-137 differs according to the diverse clinical informa-
tion of the patients such as age and grade of differentiation.
From a functional standpoint, we examined whether epigenetic
inactivation of miR-137 inhibited growth suppression in NSCLC
cells. We detected restoration of miR-137 through transfection in-
duced cell cycle G1 arrest and was able to inhibit the cell growth
in vivo and vitro. It was tempting to speculate that miR-137 may
Fig. 7. Effect of miR-137 on the growth of A549 xenografts. (A) Enhanced expression of miR-137 decreased tumor growth compared with the negative control n = 10. (B)
Proteins were extracted from tumors and subjected to western blot analysis to determine Cdc42 and Cdk6 expression levels (animals #1, #5 and #9 were shown).
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via negatively regulating Cdc42 and Cdk6 expression, the key
transducers of proliferative signals in G1cell cycle regulation
[34], which were found to be signiﬁcantly up-regulated in NSCLC
[17,25], and comforted to be as targets of miR-137 [4,15]. Given
that our study suggested that depletion of Cdc42 and Cdk6 by
miR-137 could impair the cell cycle progression, we wondered
which regulated pathways might contribute to this effect. Knock-
down of Cdc42 and Cdk6 exhibited similar effect on the lung can-
cer cell proliferation, we then evaluated the expression of Cdc42
and Cdk6 in A549 cells following the treatment of miR-137 mimic.
Not surprisingly, a markedly decrease of Cdc42 and Cdk6 expres-
sion at both mRNA level and protein level was observed in the
A549 cells transfected with miR-137mimic, moreover, the arrested
proliferation was partly restored.
Cdk6 was demonstrated to be overexpressed in NSCLC [37], and
the concept has emerged that Rb phosphorylation by Cdk4/6 leads
not only to critical E2F-dependent transcription of essential cell cy-
cle enzymes and regulators but also to assembly of the pre-replica-
tion complex in G1 phase [38]. Our date conﬁrmed that miR-137
transfection as well as Cdk6 siRNA diminished the phosphorylation
of Rb, the target of Cdk6, as previously demonstrated [6].
Cdc42, overexpressed in NSCLC, has been shown to contribute
to the regulation of cell cycle progression in G1/S-phase transition
by activation of downstream molecules such as ERK1/2 and cyclin
D1 [39], We observed that ERK1/2 and cyclin D1 expression de-
creased in NSCLC cells following treatment with miR-137 or
Cdc42 siRNA.
These functional and signaling ﬁndings strongly suggest that
miR-137 impacts on lung cancer cell behaviors by downregulating
Cdc42 and Cdk6 expression. To the best of our knowledge, this is
the ﬁrst comprehensive study to explore the role of miR-137 in
NSCLC. The combined miRNA-based and epigenetic treatment
may be a novel potential therapeutic target for lung cancer.
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